LIGAND PHARMACEUTICALS INCORPORATED Equity, Fair Value Adjustment
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Equity, Fair Value Adjustment of $31.60 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:EquityFairValueAdjustment · last filed 2025-08-08
- LIGAND PHARMACEUTICALS INCORPORATED equity, fair value adjustment for the quarter ending 2024-06-30 was $31.60M.
| Period end | Equity, Fair Value Adjustment 3 month | Equity, Fair Value Adjustment 6 month |
|---|---|---|
| 2024-06-30 | $31.60M 10-Q · filed 2025-08-08 | $31.60M 10-Q · filed 2025-08-08 |